Nuzenio

Bioaffinity Technologies

Bioaffinity Technologies news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 13 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Enterprise value to EBITDA forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingViewTradingView · Sat, 08 Aug 2026 12:10:55 GMT BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 20:53:04 GMT bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingViewTradingView · Fri, 07 Aug 2026 20:51:12 GMT BIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingViewTradingView · Fri, 07 Aug 2026 20:49:59 GMT BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingViewTradingView · Fri, 07 Aug 2026 12:36:27 GMT bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingViewTradingView · Fri, 07 Aug 2026 12:33:01 GMT bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 12:00:00 GMT Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung - MoomooMoomoo · Fri, 07 Aug 2026 12:00:00 GMT

Timeline

Sat, 08 Aug 2026 12:10:55 GMTEnterprise value to EBITDA forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView

Fri, 07 Aug 2026 20:53:04 GMTBioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Fri, 07 Aug 2026 20:51:12 GMTbioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingView

Fri, 07 Aug 2026 20:49:59 GMTBIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingView

Fri, 07 Aug 2026 12:36:27 GMTBIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingView

Fri, 07 Aug 2026 12:33:01 GMTbioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingView

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Technologies8 live mentions Inc6 live mentions Lung5 live mentions Second Quarter4 live mentions TradingView4 live mentions Results4 live mentions Continued Strong Commercial4 live mentions Momentum4 live mentions CyPath4 live mentions Yahoo Finance4 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Bioaffinity Technologies.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.